Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012))

Toni K. Choueiri, Colin Hessel, Susan Halabi, Ben Sanford, M. Dror Michaelson, Olwen Hahn, Meghara Walsh, Thomas Olencki, Joel Picus, Eric J. Small, Shaker Dakhil, Darren R. Feldman, Milan Mangeshkar, Christian Scheffold, Daniel George, Michael J. Morris

Research output: Contribution to journalComment/debate

1 Scopus citations

Abstract

The authors regret there was an error on page 120. The paragraph should read as follows (the correction has been underlined) As of the July 01, 2017, data cutoff date for OS with a median follow-up of 34.5 months (IQR 31.4–40.4), 90 deaths had occurred (43 of 79 patients in the cabozantinib group and 47 of 78 patients in the sunitinib group). The authors would like to apologise for any inconvenience caused.

Original languageEnglish
Number of pages1
JournalEuropean Journal of Cancer
Volume103
DOIs
StatePublished - Nov 2018

Fingerprint Dive into the research topics of 'Corrigendum to ‘Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update’ [Eur J Cancer 94 (May 2018) 115–125] (European Journal of Cancer (2018) 94 (115–125), (S0959804918301813) (10.1016/j.ejca.2018.02.012))'. Together they form a unique fingerprint.

  • Cite this